Company Encyclopedia
View More
name
Foyou Pharma
601089.SH
Beijing Foyou Pharma CO.,LTD engages in the research and development, production, and sale of pharmaceutical preparations and medical equipment. The company provides its products in cardiovascular system, chronic kidney disease, skin disease, digestive system, diabetes, mental nervous system, gynecology, and other therapeutic areas. It also offers disposable oxygen tube, nasal air filter, urine dynamic monitoring instrument, and urine collect bags, and other products. Beijing Foyou Pharma CO.,LTD was founded in 1999 and is headquartered in Beijing, China.
3.196 T
601089.SHMarket value -Rank by Market Cap -/-

Financial Score

08/11/2025 Update
B
PharmaceuticalsIndustry
Industry Ranking34/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE12.97%B
    • Profit Margin13.54%B
    • Gross Margin65.43%A
  • Growth ScoreC
    • Revenue YoY-0.13%D
    • Net Profit YoY-9.20%C
    • Total Assets YoY5.65%B
    • Net Assets YoY6.67%B
  • Cash ScoreC
    • Cash Flow Margin738.39%B
    • OCF YoY-0.13%D
  • Operating ScoreB
    • Turnover0.73B
  • Debt ScoreA
    • Gearing Ratio22.82%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Foyou Pharma: 6 products are expected to be selected for the 11th batch of national centralized drug procurement

    Foyou Pharma announced that six of its products are expected to be selected in the 11th batch of national centralized drug procurement, including Fumaric Acid Lurasidone Tablets, Pravastatin Sodium Tablets, Cilostazol Tablets, Alendronate Sodium Tablets, Agomelatine Tablets, and Dopamine Hydrazine Tablets. If these products are selected and sales contracts are signed, it will help increase market share and have a positive impact on the company's future operating performance. At the same time, the products that the company did not win bids for, such as Dapagliflozin Tablets, did not generate sales in 2024, and the sales amount from January to September 2025 was CNY 2.9413 million, accounting for 0.1167% of the company's operating income during the same period, which will not have a significant impact on the company's production and operations

    Zhitong·
    SH
    601089
    -0.77%
    Zhitong·
    SH
    601089
    -0.77%

    Foyou Pharma has obtained the approval notice for the listing application of Clobazam raw materials

    According to the Zhitong Finance APP, Foyou Pharma announced that it has recently received the "Approval Notice for the Market Application of Chemical Raw Materials" for Clobetasol from the National Medical Products Administration. Clobetasol is suitable for topical treatment of mild to moderate atopic dermatitis in patients aged 2 years and older. The company's acquisition of the "Approval Notice for the Market Application of Chemical Raw Materials" for Clobetasol will further enrich the company's product line and promote its continuous, stable, and healthy development

    Zhitong·
    SH
    601089
    -0.77%
    Zhitong·
    SH
    601089
    -0.77%

    Foyou Pharma's Unit Gets Registration Certificate for Dydrogesterone Tablets

    Foyou Pharma's Unit Gets Registration Certificate for Dydrogesterone Tablets

    marketscreener·
    SH
    601089
    -0.77%
    marketscreener·
    SH
    601089
    -0.77%

    Foyou Pharma: Dydrogesterone Tablets Obtained Drug Registration Certificate

    According to the Zhitong Finance APP, Foyou Pharma announced that its wholly-owned subsidiary Zhejiang Aisheng Pharmaceutical Co., Ltd. (referred to as "Zhejiang Aisheng") has received the Drug Registration Certificate for Dydrogesterone Tablets (Specification: 10mg) issued by the National Medical Products Administration, approving the production of this drug. Dydrogesterone is an orally absorbable synthetic progestogen

    Zhitong·
    SH
    601089
    -0.77%
    Zhitong·
    SH
    601089
    -0.77%

    Foyou Pharma Gets China Drug Registration Nod for Hypertension Tablets

    (MT Newswires) -- China's medical products administrator granted Beijing Foyou Pharma (SHA:601089) a drug registration certificate for its candesartan cilexetil and hydrochlorothiazide tablets for hypertension, according to a Tuesday filing with the Shanghai bourse. The original manufacturer's candesartan cilexetil-hydrochlorothiazide tablets are not available in China. Takeda and AstraZeneca jointly developed the drug, the filing said. The drug is indicated for patients with blood pressures not effectively controlled by just candesartan cilexetil or hydrochlorothiazide alone, among others. Shares closed 2% higher on Tuesday.

    marketscreener·
    SH
    601089
    -0.77%
    marketscreener·
    SH
    601089
    -0.77%